Floatz logo

Romidepsin

Common Variable Immunodeficiency

Masonic Cancer Center, University of MinnesotaSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Common Variable Immunodeficiency cohort.

Asset / SponsorPhaseRating
HUMAN IMMUNOGLOBULINS
Grifols Therapeutics LLC
Phase 3B
Anti-Thymoglobulin, Rabbit
Paul Szabolcs
Phase 2CCC
Fludarabine
Paul Szabolcs
Phase 2CCC
APILIMOD
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1CC
METHOTREXATE
Fairview University Medical Center
N/AD

View all 13 →

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Mycosis Fungoides/Sezary SyndromeDormant
BBB
Indicative ·
75 / 100
View asset →
Multiple Myeloma and Plasma Cell NeoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →